GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (FRA:SCP) » Definitions » Return-on-Tangible-Equity

Scancell Holdings (FRA:SCP) Return-on-Tangible-Equity : 0.00% (As of Oct. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Scancell Holdings Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Scancell Holdings's annualized net income for the quarter that ended in Oct. 2023 was €-5.88 Mil. Scancell Holdings's average shareholder tangible equity for the quarter that ended in Oct. 2023 was €-12.27 Mil. Therefore, Scancell Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Oct. 2023 was N/A%.

The historical rank and industry rank for Scancell Holdings's Return-on-Tangible-Equity or its related term are showing as below:

FRA:SCP's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -47.52
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Scancell Holdings Return-on-Tangible-Equity Historical Data

The historical data trend for Scancell Holdings's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings Return-on-Tangible-Equity Chart

Scancell Holdings Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -68.84 -107.56 -327.50 -140.77 -

Scancell Holdings Semi-Annual Data
Apr14 Oct14 Apr15 Oct15 Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.47 -152.50 -147.26 -1,107.51 -

Competitive Comparison of Scancell Holdings's Return-on-Tangible-Equity

For the Biotechnology subindustry, Scancell Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scancell Holdings's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's Return-on-Tangible-Equity falls into.



Scancell Holdings Return-on-Tangible-Equity Calculation

Scancell Holdings's annualized Return-on-Tangible-Equity for the fiscal year that ended in Apr. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Apr. 2023 )  (A: Apr. 2022 )(A: Apr. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Apr. 2023 )  (A: Apr. 2022 )(A: Apr. 2023 )
=-13.556/( (1.67+-10.958 )/ 2 )
=-13.556/-4.644
=N/A %

Scancell Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Oct. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Oct. 2023 )  (Q: Apr. 2023 )(Q: Oct. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Oct. 2023 )  (Q: Apr. 2023 )(Q: Oct. 2023 )
=-5.878/( (-10.958+-13.585)/ 2 )
=-5.878/-12.2715
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Oct. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Scancell Holdings  (FRA:SCP) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Scancell Holdings Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Scancell Holdings (FRA:SCP) Business Description

Traded in Other Exchanges
Address
Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (FRA:SCP) Headlines

No Headlines